A bioinformatics-based immune-related prognostic index for lung adenocarcinoma that predicts patient response to immunotherapy and common treatments

BACKGROUND: There is increasing evidence of the effectiveness of immune checkpoint blockade (ICB) therapy for the treatment of lung adenocarcinoma (LUAD). However, the benefits of ICB therapy vary among LUAD patients. Due to the research dimension, existing biomarkers, such as programmed death-ligan...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chenghao, Lu, Tong, Xu, Ran, Chang, Xiaoyan, Luo, Shan, Peng, Bo, Wang, Jun, Yao, Lingqi, Wang, Kaiyu, Shen, Zhiping, Zhao, Jiaying, Zhang, Linyou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264088/
https://www.ncbi.nlm.nih.gov/pubmed/35813746
http://dx.doi.org/10.21037/jtd-22-494

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264088/
https://www.ncbi.nlm.nih.gov/pubmed/35813746
http://dx.doi.org/10.21037/jtd-22-494

Ejemplares similares